Biolinq, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, today announced a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital..

Biolinq是一家开创精密多分析物生物传感器以改善代谢健康的医疗技术公司，今天宣布完成了由Alpha Wave Ventures领投的1亿美元C轮融资，现有投资者RiverVest Venture Partners、AXA IM Alts、LifeSci Venture Partners、M Ventures、Hikma Ventures、Aphelion Capital、Taisho Pharmaceutical和Features Capital参与了本轮融资。

Biolinq is a healthcare technology company pioneering precision multi-analyte wearable sensors to improve metabolic health. The company's biosensor platform is designed to inform and inspire with unparalleled simplicity to support healthier living. With microsensors that reside just below the skin's surface, Biolinq is redefining the future of continuous biosensing..

Biolinq是一家医疗技术公司，致力于开发精密的多分析物可穿戴传感器以改善代谢健康。该公司的生物传感器平台旨在以无与伦比的简洁性提供信息并激发灵感，助力更健康的生活方式。通过位于皮肤表面下方的微型传感器，Biolinq正在重新定义连续生物传感的未来。